Theravance Biopharma, Inc. (TBPH): Long-Term Debt
Older than the company's other figures. The latest Long-Term Debt is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.
$0
As of 2023-12-31
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2023-12-31 | $0 | n/a | 2024-03-01, Balance as of period end |
| No annual figure between 2021-12-31 and 2023-12-31. | |||
| 2021-12-31 | $616.33M | -0.5% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $619.17M | +36.1% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $455.04M | +0.2% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $454.35M | +103.1% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $223.75M | n/a | 2019-02-28, Balance as of period end |